Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announces the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”). Merck completed the cash offer at a purchase price of $221.50 per share of common stock of Cidara, without interest and subject to deduction for any required tax withholding.
Read the full article: Merck to Complete Acquisition of Cidara Therapeutics //
Source: https://www.businesswire.com/news/home/20260106167859/en/Merck-to-Complete-Acquisition-of-Cidara-Therapeutics